Guardant Health (GH) Research & Development (2017 - 2026)

Guardant Health has disclosed Research & Development across 10 years of filings, most recently posting $190.0 million for Q2 2026.

• In Q2 2026, Research & Development rose 58.84% year-over-year to $190.0 million; the TTM figure through Jun 2026 stood at $629.8 million (up 47.66% YoY), while the FY2025 annual figure was $494.7 million, up 35.55% from the prior year.
• Research & Development came in at $190.0 million for Q2 2026 at Guardant Health, up from $169.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $190.0 million in Q2 2026 to a low of $81.8 million in Q1 2022.
• Average Research & Development over 5 years is $109.1 million, with a median of $98.9 million recorded in 2022.
• Year-over-year, Research & Development fell 15.69% in 2023 and soared 62.13% in 2026.
• Over 5 years, Research & Development stood at $106.6 million in 2022, then decreased by 15.69% to $89.9 million in 2023, then grew by 16.59% to $104.8 million in 2024, then surged by 36.86% to $143.4 million in 2025, then soared by 32.48% to $190.0 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $190.0 million in Q2 2026, $169.1 million in Q1 2026, and $143.4 million in Q4 2025.